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Nephrogenic Systemic Fibrosis:
Considerations for the Cardiologist*
Neil M. Rofsky, MD
Boston, MassachusettsThe manuscript by Schietinger et al. (1) in this issue
of iJACC (JACC: Cardiovascular Imaging) assesses
patterns of late gadolinium enhancement (LGE) in
the myocardium of chronic hemodialysis patients.
The observation that the majority of LGE was not
infarct related but was tied to the degree of left
ventricular hypertrophy, particularly in dysfunctional
segments, led the authors to suggest that LGE pat-
terns within the myocardium may be able to serve as a
clinical marker, perhaps for sudden death.
See page 450
However, the prospect for investigating such
potential has been quelled by the new reality of
nephrogenic systemic fibrosis (NSF). During the
course of the Schietinger et al. (1) study, an emerg-
ing awareness of NSF, particularly in this highest-
risk chronic hemodialysis population, and the iden-
tification of a new NSF case within their cohort
forced its premature termination.
Nephrogenic systemic fibrosis is a systemic
fibrosing disorder strongly associated with the
administration of gadolinium-based contrast agents
(GBCAs) in patients with substantial renal disease
(2–4). The available data suggest a 3% to 7%
prevalence in the vulnerable population (4,5), al-
though prevalence determination is problematic (5).
First reported in 2000 by Cowper et al. (6) as a
unique fibrosing disorder that was recognized among
patients undergoing renal dialysis, an early term as-
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mopathy, emanated from its dermal manifestations.
The recognition of systemic involvement prompted
a change in the name of the disorder to NSF (7). The
clinical manifestations of NSF are highly variable
spanning from a tiny plaque on the lower extremities
to severe contractures and death. Not until 2006 was it
first suggested that some of the GBCAs may trigger
the development of NSF (2,3). The functional conse-
quences of NSF are often debilitating and may be
fatal. Treatment is multidisciplinary, predominantly
supportive, and largely ineffective.
Nephrogenic systemic fibrosis is most commonly
observed in patients with at least stage 4 chronic
kidney disease (CKD), when the estimated glomer-
ular filtration rate (eGFR) is 30 ml/min per 1.73
m2, with a clear majority noted in dialysis patients.
While NSF has not been documented in CKD
patients having an eGFR 30 ml/min per 1.73 m2,
it has been seen in acute renal failure patients with
higher eGFR values, particularly with concurrent
pro-inflammatory processes (4,8).
To highlight the risk posed to patients with
kidney problems, a black box warning on the
product labels of all 5 of the GBCAs approved in
the U.S. has been added in response to a request by
the U.S. Food and Drug Administration. A sum-
mary of some of the important observations regard-
ing NSF follows. Most of the epidemiological data
have been gathered using the unreliable strategy of
self-reporting. Published studies are chiefly retro-
spective reviews of relatively small populations
(each typically 40 individuals). The documenta-
tion of the type and dose of GBCA has been poor.
The largest number of cases is associated with
exposure to the GBCA, gadodiamide. The associ-
ation between NSF and GBCA use is preponderant
but not universal (9). The onset of noticeable
disease is unpredictable with respect to the time of
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458xposure, and there are relatively low numbers of
eported cases given the historical prolific use of
BCAs in renal insufficiency patients.
The predominant mechanistic hypothesis for
SF involves the liberation of free gadolinium (Gd)
rom its binding molecule, thought to trigger an
nflammatory response. Support for this hypothesis
esides in data demonstrating gadolinium in skin
iopsy specimens of NSF patients (8) and in exper-
mental studies in both humans (10) and animals
11). However, an as yet unidentified cofactor may
e operative.
Gadolinium belongs to the lanthanide series, a
et of chemically related elements with atomic
umbers from 57 to 71 that have unpaired elec-
rons. The interactions between the unpaired elec-
rons of the gadolinium ion and the hydrogen nuclei
f water molecules in tissues augment image contrast.
owever, the bare gadolinium metal ion is highly
oxic. Therefore, it is essential that it be bonded to
n organic moiety or ligand to provide a metal
helate complex (e.g., Gd-DTPA, Gd-BOPTA,
d-DOTA, and so on) for altering image contrast.
The variable risk of NSF among the different
BCAs may be attributable to differences in the
hemical stability of agents, a reflection of the
ropensity with which they are likely to dissociate
nd release free Gd3 in vivo. The physical param-
ter that is most compelling to guide clinical prac-
ice from a chemistry perspective is the kinetic
tability of an agent (12). The greater the kinetic
tability, the less likely it is for an agent to dissoci-
te. The biological relevance of the kinetic proper-
ies of several contrast agents was reported in a
tudy showing strong correlation between the dis-
ociation rates of chelates in acid and the long-term
eposition of Gd3 in rat tissues (11).
Given that the clinical and epidemiological data
re relatively sparse, the chemical and physical
onsiderations support the use of a subset of the
vailable Gd-chelates with strong kinetic stabilities,
he macrocyclic agents, since they are far less likely
o dissociate (12,13). This is particularly the case for
atients with an eGFR 30 ml/min/1.73 m2. A
ecent report showing no cases of NSF in long-term
emodialysis patients after administration of the
acrocyclic agent (gadoteridol) supports this per-
pective (14).
Institutional policies and procedures are evolving
o address the exposure to GBCAs in patients at
isk for NSF. A variety of screening procedures to
dentify patients with low eGFR rates, increased
ttention to the types and doses of contrast agent hdministered, alterations in imaging strategies, and
ducation at all levels of the medical community are
mportant components to such initiatives. The use
f screening forms and routine venous sampling for
erum creatinine values before Gd-enhanced mag-
etic resonance imaging are becoming pervasive.
hese procedures help address the limited aware-
ess of kidney disease in patients with stage 4 and 5
KD who are not yet on dialysis. However, cir-
umstances in which a high-risk individual requires
 GBCA to facilitate their management will arise.
n this scenario, an informed consent process spe-
ifically addressing the risk for NSF should be
pplied.
For myocardial scar and fibrosis imaging inver-
ion recovery sequences with an inversion time
tructured to null the normal myocardium are used
o optimize the contrast between the tissue retain-
ng gadolinium (scar) and the healthy or viable
yocardium (15). Options to alter the time be-
ween contrast administration and imaging, to ad-
ust inversion times, to use agents with high relax-
vity (T1 “brightening” capability), and to image at
igh field strength offer opportunities for dose
eduction with potential to reduce NSF risk
16,17). Such optimization, coupled with the use of
acrocyclic agents, could broaden the opportunities
or efficacious imaging in patients at risk for NSF.
he increased imperative for contrast media-
ndependent techniques capable of demonstrating
yocardial viability will revive important lines of
esearch in diffusion, phosphorus, and sodium-
ased magnetic resonance evaluations (18 –20).
Prospective registries that have recently been
nitiated or are soon to be, as mandated of the
anufacturers by the U.S. Food and Drug Admin-
stration, will likely generate more reliable data
egarding the incidence, prevalence, potential co-
actors, and the degrees of severity of this disorder.
t is hoped that from such data refined strategies
ill emerge to guide the best risk: benefit selections
or patients requiring GBCAs for their care.
Thus, the provocative data from Schietinger et al.
1) cannot be further validated or advanced until
ssues related to NSF in this population are ade-
uately addressed. Knowledge regarding the risks of
SF in this vulnerable group will help to minimize
his potentially devastating iatrogenic disorder.
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